



Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference

July 14, 2022

BOSTON--(BUSINESS WIRE)--Jul. 14, 2022-- [Astria Therapeutics, Inc.](#) (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a virtual fireside chat at the upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference on Wednesday, July 20, at 12:30pm ET.

A webcast of the event can be accessed at the following link: <https://journey.ct.events/view/519a557c-f4a1-4383-85fa-e0f4e35d70d4>. An archived replay of the event will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20220714005129/en/>

Investor relations:

Andrea Matthews

investors@astriatx.com

Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.